The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; email:
Annu Rev Med. 2021 Jan 27;72:199-213. doi: 10.1146/annurev-med-052919-120048.
Ulcerative colitis (UC) is a relapsing and remitting inflammatory disease of the colon with a variable course. Despite advances in treatment, only approximately 40% of patients achieve clinical remission at the end of a year, prompting the exploration of new treatment modalities. This review explores novel therapeutic approaches to UC, including promising drugs in various stages of development, efforts to maximize the efficacy of currently available treatment options, and non-medication-based modalities. Treatment approaches which show promise in impacting the future of UC management are highlighted.
溃疡性结肠炎（UC）是一种反复发作和缓解的结肠炎症性疾病，其病程具有多变性。尽管在治疗方面取得了进展，但只有大约 40%的患者在一年内达到临床缓解，这促使人们探索新的治疗方式。本综述探讨了 UC 的新型治疗方法，包括处于不同开发阶段的有前途的药物、努力最大限度地提高现有治疗方案的疗效以及非药物治疗方法。本文强调了在影响 UC 管理未来方面有希望的治疗方法。
